US › Healthcare

Kyntra Bio, Inc. (KYNB)

US · Healthcare · Biotechnology

$6.92+2.37%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$3.7M
Revenue YoY
+36.5%
Net profit
$-15.2M
Profit YoY
-427.6%
EPS
$-3.76
EPS estimate
$-3.35
Net margin
-406.6%

EPS came in at -3.76 against a street estimate of -3.35 — a miss of 12.2%.

Key statistics

Market cap
$27.2M
Forward P/E
61.3
P/B
80.40
Book value
$-10.82
EPS (TTM)
$-14.32
52-week high
$12.60
52-week low
$6.32
50-day MA
$7.05
200-day MA
$7.97
Beta
0.97

Analyst view

with an average price target of $39.00.

Shareholding

Insiders
2.02%
Institutions
25.57%

Largest institutional holders

FundStake
Armistice Capital, LLC9.88%
Vanguard Capital Management, LLC3.87%
Acadian Asset Management LLC2.61%
BlackRock Inc2.08%
Two Sigma Investments LLC1.22%
Geode Capital Management, LLC1.14%
HighTower Advisors, LLC0.98%
UBS Group AG0.68%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Kyntra Bio, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.